Apellis Pharmaceuticals, Inc.
http://www.apellis.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apellis Pharmaceuticals, Inc.
AstraZeneca Hopes Danicopan Interim Data Will Prove Sufficient For NDA Filing
Danicopan seen as potential add-on therapy for paroxysmal nocturnal hemoglobinuria patients getting suboptimal results from Soliris or Ultomiris therapy. AstraZeneca will investigate filing for approval on 12-week data.
Iveric's Zimura Shows Benefit In Geographic Atrophy, An Area Poised For New Options
The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.
Keeping Track: Incyte’s Opzelura Earns First Vitiligo Claim; NDAs From Apellis, Acadia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Sobi Returns To Deal-Making With ADC Lymphoma Licensing Pact
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals